Physician profile
David T Pride
NPI 1194875526
$59,917.05
in general payments reported to CMS, 2019-2025
12 companies · $3,661 in 2025
The $3,661 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2021: $6,263 · 2022: $17K · 2023: $16K · 2024: $1,167 · 2025: $3,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,767 · Travel and Lodging: $2,026 · Consulting Fee: $885 · Food and Beverage: $212 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,231.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,767.00 |
| Travel and Lodging | $2,026.28 |
| Consulting Fee | $885.00 |
| Food and Beverage | $212.01 |
| Education | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $26,796.93 | 2019-2025 | Cobas 8000 Core Unit, Cobas Hbv/Hcv/Hiv-1 Control Kit, Cobas 6800 System |
| Gen-Probe, INC. | $14,479.47 | 2019-2025 | None, Aptima |
| Cepheid | $6,299.53 | 2022-2025 | Genexpert |
| Biofire Diagnostics, LLC | $4,732.63 | 2019 | |
| Quidel Corporation | $3,000.00 | 2019 | |
| Hologic Sales and Service, LLC | $2,275.15 | 2023 | Aptima, Panther Fusion |
| Roche Molecular Systems, INC. | $2,200.00 | 2019-2022 | |
| Hologic INC | $40.56 | 2022 | |
| Genmark Diagnostics, INC. | $40.21 | 2025 | Eplex |
| Beckman Coulter, INC. | $29.45 | 2024 | |
| Accelerate Diagnostics INC. | $23.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.